Efficacy of Dietary Interventions and Probiotic Use in the Management of Gastrointestinal Disorders in Older Adult
DOI:
https://doi.org/10.56294/shp2024142Keywords:
Probiotics, Dietary Changes, Gastrointestinal Disorders, Older Adults, Constipation, Gut HealthAbstract
Background: Older adults experience physiological changes and alterations in the gut microbiota that can significantly impact gastrointestinal health. These changes, alongside the high prevalence of digestive disorders in this population, underscore the need for targeted interventions to improve well-being. Dietary modifications and probiotic supplementation have emerged as promising strategies for managing these symptoms; however, further research is needed to fully understand their effectiveness in this age group. Materials and Methods: A literature search was conducted in databases such as PubMed and the Cochrane Library, focusing on studies published in the last 20 years. Studies examining the relationship between dietary changes, probiotic use, and gastrointestinal disorders in older adults were included. Data analysis was performed using a qualitative and descriptive approach, integrating and evaluating information from the selected studies. Statistical analysis was deemed unnecessary due to the heterogeneity of the studies or the nature of the results, with a focus on evaluating and integrating the available evidence. Results: Probiotics such as Lactobacillus rhamnosus GG, Bifidobacterium, and mixtures like VSL#3 were shown to reduce intestinal inflammation, improve gut microbiota, and relieve gastrointestinal symptoms, including abdominal pain, bloating, and constipation, in older adults. In some studies, probiotics were found to be comparable to standard medications like mesalazine in the treatment of ulcerative colitis. Conclusion: Probiotic use and dietary interventions are promising approaches for improving gastrointestinal disorders in older adults. These interventions not only enhance gut health but could also reduce polypharmacy and improve quality of life. Nevertheless, despite encouraging findings, further well-designed studies are required to better understand the mechanisms involved and to determine the most effective strategies for sustainably enhancing gastrointestinal health in older adults.
References
1. Organización Mundial de la Salud. Envejecimiento y salud [Internet]. Ginebra: OMS; 2022 [citado 2024 Jul 13]. Disponible en: http://www.who.int/es/news-room/fact-sheets/detail/envejecimiento-y-salud
2. Anand R, Song Y, Garg S, Girotra M, Sinha A, Sivaraman A, et al. Effect of aging on the composition of fecal microbiota in donors for FMT and its impact on clinical outcomes. Dig Dis Sci. 2017;62(4):1027-36. doi:10.1007/s10620-017-4449-6
3. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller L, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(S1). doi:10.1038/ajg.2014.187
4. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337
5. Kaminski M, Skonieczna-Zydecka K, Loniewski I, Koulaouzidis A, Marlicz W. Are probiotics useful in the treatment of chronic idiopathic constipation in adults? A review of existing systematic reviews, meta-analyses, and recommendations. Prz Gastroenterol. 2020;15(2):103-18
6. Goetze O, Fruehauf H, Pohl D, Giarrè M, Rochat F, Ornstein K, et al. Effect of a prebiotic mixture on intestinal comfort and general wellbeing in health. Br J Nutr. 2008;100(5):1077-85
7. Wen Y, Li J, Long Q, Yue CC, He B, Tang XG. The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials. Int J Surg. 2020;79:111-9. doi:10.1016/j.ijsu.2020.04.063
8. Sánchez-Rodríguez JR, Escare-Oviedo CA, Castro-Olivares VE, Robles-Molina CR, Vergara-Martínez MI, Jara-Castillo CT. Polifarmacia en adulto mayor, impacto en su calidad de vida. Revisión de literatura. Rev Salud Pública. 2019;21(2):271-7. Disponible en: https://doi.org/10.15446/rsap.V21n2.76678
9. Aragon G, Graham DB, Borum ML, Doman DB. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (N Y). 2010;6(1):39-44
10. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(5):508-18
11. Chang L. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Expert Rev Gastroenterol Hepatol. 2010;4(1):87-98
12. Quigley EM. Gut microbiota and the role of probiotics in therapy. Curr Opin Pharmacol. 2011;11(6):593-603
13. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008;53(10):2714-8
14. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9(6):461-9
15. Min YW, Park SU, Jang YS, Kim YH, Rhee PL, Ko SH, et al. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis on irritable bowel syndrome: a randomized controlled trial. World J Gastroenterol. 2012;18(33):4563-9.
Published
Issue
Section
License
Copyright (c) 2024 Josiany Maria Barboza , Karina Bustamente Galarza (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
